Cover Image
市場調查報告書

再生醫療與幹細胞治療:帶來治癒希望的未來的醫藥品

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure

出版商 MP Advisors 商品編碼 323218
出版日期 內容資訊 英文 98 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療與幹細胞治療:帶來治癒希望的未來的醫藥品 Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
出版日期: 2015年01月21日 內容資訊: 英文 98 Pages
簡介

近幾年,全球各國進行再生治療和細胞療法/幹細胞治療相關研究,醫藥品上市的可能性顯現出來。透過幹細胞治療等有效利用,到現在為止被認為是無法治療的慢性疾病(糖尿病、肥胖症、關節炎等)和癌症,老化伴隨而來的疾病(癡呆症等),變得可能治療。並且,預期帶來巨大的市場機會。

本報告提供全球各國再生醫療及細胞治療、幹細胞治療的最新開發情形和今後的市場趨勢的分析、幹細胞治療概要,及全球各國的最新開發、認證情形、圍繞現在已上市/已通過核準的醫藥品的形勢、今後的技術開發的方向性與市場成長可能性、主要企業簡介及技術開發情形的資訊彙整,為您概述為以下內容。

摘要整理

  • 揭開再生醫療/幹細胞治療的「黃金時代」的序幕

簡介

  • 幹細胞的種類
  • 間葉系肝細胞(MSC)
  • 困難的選擇:是「自我」移植治療還是「同種異體」移植治療

法規方案

  • 日本和亞洲各國領先
  • 日本的適應性認證法規
  • 韓國的管理體制現況
  • 印度的管理體制現況
  • 美國、EU的法規方案

已上市的細胞/幹細胞產品

  • 在韓國和全球各國已認證的細胞/幹細胞產品
  • 已經過核准治療方法的治療費

發展與課題

  • 已認證細胞治療醫療費也能償還!

企業合併、收購(M&A):再生醫療市場活躍

在特定的治療領域的進步

  • 糖尿病
  • 心血管疾病
  • 肌肉骨骼(MSD)相關的症狀
  • 眼性疾病

再生醫療、幹細胞治療的專業企業中,今後有代表性的里程碑(2015∼16年)

分析對象企業

  • CESCA Therapeutics Inc. (KOOL)
  • OCAtA Therapeutics Inc. (OCAT)
  • Orgenesis (ORGS)
  • TiGenix NV (TIG:BB)
  • Pluristem Therapeutics Inc (PSTI:IT)
  • Mesobalst Ltd (MSB:AU)
  • Medipost Co. Ltd (078160:KS)
  • JCR製藥 (4552:JP)
  • 日本、Engineering Co (7774:JP)

附錄

目錄
Product Code: 4473

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines.

Therapy class report: "Regenerative Medicine and Stem cell based Cell therapies- Drugs of the Future Offering Hope for Cure".

This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. The therapy class report highlights the future potential of this stream of medicine and the radical way in which diseases could be treated in the next few decades. This new stream of medicine is driven by landmark scientific discoveries and research (Nobel prize in 2012).

In recent years, the translation of research into the clinic has been spearheaded by Rising stars companies (RS). Some of them have come in the limelight because of their technology platform, clinical data, successful IPO, etc. We expect most of these home grown technologies/products developed by the RS/ Research collaborations to fuel the pipeline of large pharma through acquisition or collaboration when the drug is in late stage or approved. The Regenerative medicine Universe is large and new companies are rapidly becoming a part of this universe. . As a result, we have used some filters to select a few names for a detailed coverage in our Outlook this year. Needless to say, that this could just be the tip of the iceberg!

Key Criteria for Our Selection:-

  • Uniqueness of the Technology platform and the ability to scale up
  • Commercial value in case of positive outcome of the products in the pipeline
  • Pipeline and clinical data analysis
  • Marketed product and commercial tie up. Robustness of the Management, financial and business model.

Table of Contents

Table of Contents

Executive summary

  • Dawn of the Golden Era for Regenerative Medicine/Stem cell based therapies

Introduction

  • Stem cells Types
  • Mesenchymal stem cells (MSCs
  • Tough Choice- "Autologous vs. Allogenic " Therapies

Regulatory Scenario

  • Japan and Asia Lead the Way
  • Japanese Adaptive Licensing Legislation
  • South Korea Regulatory Update
  • India Regulatory Update
  • Regulatory Scenario in US and EU

Marketed Cell based/Stem Cell Products

  • Approved Cell-based / Stem Cell Therapies in Korea and WW
  • Cost of Treatment of Approved Therapies

Progress and Challenges

  • Reimbursement of Approved Cell based Therapies!

Merger and Acquisition- Gaining Momentum in Regenerative Space

Progress in Specific Therapy Areas

  • Diabetes
  • Cardiovascular Disease
  • Musculoskeletal (MSD) Related Conditions
  • Ocular Disease

SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM CELL FOCUSED COMPANIES (2015-16)

COMPANY COVERAGE

  • 1. CESCA Therapeutics Inc. [KOOL]
  • 2. OCAtA Therapeutics Inc.[OCAT]
  • 3. Orgenesis [ORGS]
  • 4. TiGenix NV[ TIG:BB]
  • 5. Pluristem Therapeutics Inc [PSTI:IT]
  • 6. Mesobalst Ltd [MSB:AU]
  • 7. Medipost Co. Ltd [078160:KS]
  • 8. JCR Pharmaceuticals [4552:JP]
  • 9. Japan Tissue Engineering Co., Ltd [7774:JP]

Appendix

Back to Top